PL3224253T3 - Pochodne bis(sulfonoamidu) i ich zastosowanie jako inhibitorów mpges - Google Patents

Pochodne bis(sulfonoamidu) i ich zastosowanie jako inhibitorów mpges

Info

Publication number
PL3224253T3
PL3224253T3 PL15862932T PL15862932T PL3224253T3 PL 3224253 T3 PL3224253 T3 PL 3224253T3 PL 15862932 T PL15862932 T PL 15862932T PL 15862932 T PL15862932 T PL 15862932T PL 3224253 T3 PL3224253 T3 PL 3224253T3
Authority
PL
Poland
Prior art keywords
sulfonamide
bis
derivatives
mpges inhibitors
mpges
Prior art date
Application number
PL15862932T
Other languages
English (en)
Inventor
Peter SÖDERMAN
Mats A SVENSSON
Annika Kers
Liselott ÖHBERG
Katharina HÖGDIN
Andreas Hettman
Jesper Hallberg
Maria Ek
Johan Bylund
Johan NORD
Original Assignee
Gesynta Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gesynta Pharma Ab filed Critical Gesynta Pharma Ab
Publication of PL3224253T3 publication Critical patent/PL3224253T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15862932T 2014-11-27 2015-11-24 Pochodne bis(sulfonoamidu) i ich zastosowanie jako inhibitorów mpges PL3224253T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1451436 2014-11-27
EP15862932.9A EP3224253B1 (en) 2014-11-27 2015-11-24 Bis (sulfonamide) derivatives and their use as mpges inhibitors
PCT/SE2015/051262 WO2016085392A1 (en) 2014-11-27 2015-11-24 Bis(sulfonamide) derivatives and their use as mpges inhibitors

Publications (1)

Publication Number Publication Date
PL3224253T3 true PL3224253T3 (pl) 2020-05-18

Family

ID=56074771

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15862932T PL3224253T3 (pl) 2014-11-27 2015-11-24 Pochodne bis(sulfonoamidu) i ich zastosowanie jako inhibitorów mpges

Country Status (14)

Country Link
US (1) US10081614B2 (pl)
EP (1) EP3224253B1 (pl)
JP (1) JP6649538B2 (pl)
CN (1) CN107001309B (pl)
CY (1) CY1122561T1 (pl)
DK (1) DK3224253T3 (pl)
ES (1) ES2765490T3 (pl)
HR (1) HRP20200043T1 (pl)
HU (1) HUE047857T2 (pl)
PL (1) PL3224253T3 (pl)
PT (1) PT3224253T (pl)
RS (1) RS59741B1 (pl)
SI (1) SI3224253T1 (pl)
WO (1) WO2016085392A1 (pl)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4054369B2 (ja) * 2004-05-04 2008-02-27 ファイザー株式会社 オルト置換アリールまたはヘテロアリールアミド化合物
EP1934173A1 (en) 2005-10-13 2008-06-25 Biolipox AB Naphthalene-disulfonamides useful for the treatment of inflammation
WO2008129288A2 (en) 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
WO2008129276A1 (en) 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
UY31468A1 (es) 2007-11-15 2009-07-17 Derivados bis-(sulfonilamino) en terapia 065
TW200930369A (en) * 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
US20090163586A1 (en) * 2007-12-20 2009-06-25 Astrazeneca Ab Bis-(Sulfonylamino) Derivatives in Therapy 205
WO2010132016A1 (en) 2009-05-14 2010-11-18 Astrazeneca Ab Bis-(sulfonylamino) derivatives for treatment of pain and inflammation
WO2016085391A1 (en) * 2014-11-27 2016-06-02 Acturum Life Science AB Bis(sulfonamide) derivatives and their use as mpges inhibitors

Also Published As

Publication number Publication date
EP3224253A1 (en) 2017-10-04
CN107001309B (zh) 2021-03-05
US10081614B2 (en) 2018-09-25
DK3224253T3 (da) 2019-12-09
ES2765490T3 (es) 2020-06-09
PT3224253T (pt) 2020-01-20
EP3224253A4 (en) 2018-05-09
HRP20200043T1 (hr) 2020-03-20
HUE047857T2 (hu) 2020-05-28
EP3224253B1 (en) 2019-10-30
JP2017538784A (ja) 2017-12-28
CN107001309A (zh) 2017-08-01
RS59741B1 (sr) 2020-02-28
WO2016085392A1 (en) 2016-06-02
JP6649538B2 (ja) 2020-02-19
CY1122561T1 (el) 2021-01-27
SI3224253T1 (sl) 2020-02-28
US20170313672A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
ZA201700241B (en) Mnk inhibitors and methods related thereto
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
UA31653S (uk) Курильне приладдя
IL248264B (en) History of 5-oxy-pyridizin-3-one and herbicides containing them
BR112016030697A2 (pt) inibidores da desmetilase-1 específica da lisina
HK1226398A1 (zh) 作為midh1抑制劑的苯並咪唑-2-胺
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
IL252560A0 (en) Heterocyclic derivatives and their uses
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
HK1232227A1 (zh) 作為 抑制劑的喹嗪酮衍生物
HK1250161B (zh) 6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途
EP3148967A4 (en) Sulfonamide compounds and their use as stat5 inhibitors
HK1250028A1 (zh) 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途
HK1252767A1 (zh) 作為eaat3抑制劑的吡唑-吡啶衍生物
EP3224241A4 (en) Bis(sulfonamide) derivatives and their use as mpges inhibitors
ES1124632Y (es) Tabla de Salvamento
ES1119705Y (es) Tabla para rescate
HUE047857T2 (hu) Bisz(szulfonamid) származékok és felhasználásuk mPGS-inhibitorként
IL247872A0 (en) stat5 inhibitors and their uses
GB201418154D0 (en) Inhibitors
GB201409661D0 (en) Novel compounds and their use as kinase inhibitors
TH1501006052A (th) สารยับยั้ง bacei
GB201405532D0 (en) Novel compounds and their use as Kinase inhibitors